Heparin excretion in intact and hepatectomized rats

Area of Science:

• Pharmacology
• Biochemistry
• Toxicology

Background:

• Heparin is a widely used anticoagulant.
• Understanding heparin's metabolism and excretion is crucial for its safe and effective clinical use.
• The role of the liver in heparin's pharmacokinetic profile remains incompletely understood.

Purpose of the Study:

• To investigate the metabolic fate and excretion kinetics of heparin.
• To determine the influence of the liver on heparin's anticoagulant activity and elimination.
• To compare heparin's behavior in intact versus hepatectomized rats.

Main Methods:

• Tritium-labeled heparin (3H-heparin) was administered to three groups of rats: intact with biliary fistulas, intact without fistulas, and hepatectomized.
• Radioactivity was measured in blood, bile, and urine.
• Anticoagulant activity (APTT) was assessed in blood and urine.
• Urine metabolites were analyzed using column chromatography.

Main Results:

• Intact rats excreted 70-80% of the radioactive dose in urine within 48 hours, with minimal excretion into bile (around 5%).
• Anticoagulant activity rapidly normalized in intact rats.
• Hepatectomized rats showed significantly reduced urinary excretion (25% in 24 hours) and a slower decline in anticoagulant activity.
• The primary urinary radioactive component was consistent with unchanged heparin.

Conclusions:

• The liver plays a minimal role in the regulation of heparin's anticoagulant effects.
• Heparin's excretion and anticoagulant activity are not significantly dependent on hepatic function.
• Heparin is primarily eliminated unchanged via the kidneys.